natgillin/translations-raw huggingface dataset:
L-Argininhydrochlorid L-Methionin Polysorbat 80
L-Arginine hydrochloride L-Methionine Polysorbate 80
L-ASP (6.000 IE/m2, i.m.): dag 44
L-ASP (6000 IUnits/m2, IM): day 44
L-ASP (6.000 IE/m², i.m.): dag 44
L-ASP (6000 IUnits/m2, IM): day 44
L-ASP (6000 IE/m2,i.m.): dag 44
L-ASP (6000 IUnits/m2, IM): day 44
L-ASP (6000 IE/m²,i.m.): dag 44
L-ASP (6000 IUnits/m2, IM): day 44
L-glutamin Natriumbikarbonat Hepes
L-glutamine Sodium bicarbonate Hepes
L-Glutaminsyre, L-Phenylalanin,
L-Glutamic acid, L-Phenylalanine,
L-histidin hydrochlorid monohydrat L-methionin
L-histidine hydrochloride monohydrate L-methionine
L-histidin hydrochloridmonohydrat
L-histidine hydrochloride monohydrate
L-histidin hydrochlormonohydrat
L-histidine hydrochloride monohydrate
L-histidin Mannitol
L-histidine Mannitol
L-Histidin Polysorbat 80
L-Histidine Polysorbate 80
L-histidin, L-histidinmonohydrochloridmonohydrat, L-arginin, L-argininhydrochlorid, L- methionin, polysorbat 80, vand til injektionsvæsker.
L-Histidine, L-Histidine monohydrochloride monohydrate, L-Arginine, L-Arginine hydrochloride, L- Methionine, Polysorbate 80, Water for injections.
L-histidineonohydrochloridmonohydrat Polysorbat 80
L-Histidine monohydrochloride monohydrate Polysorbate 80
L-histidinhydrochlorid monohydrat Polysorbat 80
L-histidine hydrochloride monohydrate Polysorbate 80
L-histidinhydrochlorid, L-histidin
L-histidine hydrochloride L-histidine
L-histidinhydrochlorid, L-histidin, polysorbat 20, ,-trehalosedihydrat.
L-histidine hydrochloride, L-histidine, polysorbate 20, ,-trehalose dehydrate.
L-Isoleucin, L-Threonin,
L-Isoleucine, L-Threonine,
L-Leucin, L-Isoleucin,
L-Leucine,
L-methionin Nitrogen
L-methionine Nitrogen
L-Olanda/Nederland/Nederland/Niederlande/Holandia/Países Baixos/ Olanda/Nizozemska/Holandsko/Alankomaat/Nederländerna/Nederländerna Tel./тел./tlf./τηλ./ Sími/τηλ./Tlf./Puh./
L-Olanda/Nederland/Nederland/Niederlande/Holandia/Países Baixos/ Olanda/Nizozemska/Holandsko/Alankomaat/Nederländerna/Nederländerna Tel./тел./tlf./τηλ./Sími/τηλ./Tlf./Puh./
L-prolin er en fysiologisk, ikke- essentiel aminosyre.
L-proline is a physiological, non- essential amino acid.
L-Threonin,
L-Isoleucine, L-Threonine,
L. interrogans serogruppe Australis serovar Bratislava for at begrænse infektion.
L. interrogans serogroup Australis serovar Bratislava to reduce infection
L. interrogans serogruppe Canicola serovar Canicola for at begrænse infektion og udskillelse i urin.
L. interrogans serogroup Canicola serovar Canicola to reduce infection and urinary excretion
L. interrogans serogruppe Icterohaemorrhagiae serovar Copenhageni for at begrænse infektion og udskillelse i urin.
L. interrogans serogroup Icterohaemorrhagiae serovar Copenhageni to reduce infection and urinary excretion
L. kirschneri serogruppe Grippotyphosa serovar Bananal/Lianguang for at begrænse infektion og udskillelse i urin.
L. kirschneri serogroup Grippotyphosa serovar Bananal/Lianguang to reduce infection and urinary excretion
L. kirschneri serogruppe Grippotyphosa serovar Bananal/Lianguang for at begrænse infektion og udskillelse i urin.
L. kirschneri serogroup Grippotyphosa serovar Bananal/Lianguang to reduce infection and urinary excretion.
L. kirschneri serogruppe Grippotyphosa serovar Grippotyphosa.
L. kirschneri serogroup Grippotyphosa serovar Grippotyphosa.
L.I.D. 1ère Avenue – 2065m F-06516 CARROS
L.I.D. 1ère Avenue - 2065 m 06516 CARROS
L.I.D. 1ére Avenue – 2065m F-06516 CARROS
L.I.D. 1ère Avenue - 2065 m 06516 CARROS
l/time/m²
l/h/m2
L106R
E103X
L120P
L120S
L120S
L120V
L129P
K127X
L131P
K130R
L167P
L167Q
L167Q
D165V
L272 af 25.10.96
Sodium chlorided
L272 af 25.10.96 d OJ nr.
dl--tocopherol acetatea (Vitamin E)
L28V-substitutionen i HCV- NS5A reducerede følsomheden over for ombitasvir med 21 gange.
Substitution L28V in HCV NS5A reduced the susceptibility to ombitasvir by 21-fold.
L290 af 05.12.95
Annex II of Council Regulation (EEC) No 2377/90
L290 af 05.12.95 e OJ nr.
Potassium chlorideb (E508)
L290 af 05.12.95 g OJ nr.
Simethiconeg (Dimethicone)
L300F
D299E
L300P
L300F
L310F
A309P
L311V
L310F
La administración de 60 mg/kg p.c./día de hidroxicarbamida a ratas macho (aproximadamente el doble de la dosis máxima recomendada en seres humanos) les produjo atrofia testicular, reducción de la espermatogénesis y reducción acusada de la capacidad de preñar a las hembras.
Hydroxycarbamide administered to male rats at 60 mg/kg b.w./day (about double the recommended usual maximum dose in humans) produced testicular atrophy, decreased spermatogenesis and significantly reduced their ability to impregnate females.
La administración de una vacuna con virus vivo a un paciente en tratamiento con hidroxicarbamida puede desencadenar una infección grave.
Vaccination with a live vaccine in a patient taking hydroxycarbamide may result in severe infections.
La administración de una vacuna con virus vivos a un paciente en tratamiento con hidroxicarbamida puede desencadenar una infección grave.
Vaccination with a live vaccine in a patient taking hydroxycarbamide may result in severe infections.
La anemia de células falciformes es un trastorno de la sangre hereditario que afecta a los glóbulos rojos de la sangre con forma redondeada.
Sickle Cell disease is an inherited blood disorder that affects the disc shaped red cells of the blood.
La biodisponibilidad oral de la hidroxicarbamida es casi completa a juzgar por lo observado en otras indicaciones distintas de la anemia drepanocítica.
The oral bioavailability of hydroxycarbamide is almost complete as assessed in indications other than Sickle Cell Syndrome.
La Cuesta, Sector 3 50100 La Almunia de Doña Godina
Ind. La Cuesta, Sector 3 50100 La Almunia de Doña Godina
La depresión medular es el efecto tóxico limitante de la dosis de hidroxicarbamida.
Bone marrow depression is the dose-limiting toxic effect of hydroxycarbamide.
La dosis inicial de hidroxicarbamida es de 15 mg/kg de peso corporal, y la dosis habitual es de 15 a 30 mg/kg de peso corporal/día.
The starting dose of hydroxycarbamide is 15 mg/kg b.w. and the usual dose is between 15 and 30 mg/kg b.w./day.
La dosis prescrita de Siklos debe tomarse una vez al día, preferiblemente por la mañana antes de desayunar.
The prescribed dose of Siklos must be taken once daily, preferably in the morning before breakfast.
La duración del tratamiento es responsabilidad del médico, y dependerá de la situación clínica y hematológica de cada paciente.
The duration of treatment is the responsibility of the treating physician and should be based on the clinical and haematological status of the individual patient.
La eliminación del medicamento no utilizado y de todos los materiales que hayan estado en contacto con él, se realizará de acuerdo con la normativa local.
Any unused product or waste material should be disposed of in accordance with local requirements.
La embriotoxicidad se caracterizó por reducción de la viabilidad fetal, reducción del tamaño de las camadas vivas y retrasos del desarrollo.
Embryotoxicity was characterized by decreased foetal viability, reduced live litter sizes, and developmental delays.
La embriotoxicidad se caracterizó por reducción de la viabilidad fetal, reducción del tamaño de las camadas vivas y retrasos del desarrollo.
Embryotoxicity was characterized by decreased foetal viability, reduced live litter sizes, and developmental delays..
La evaluación de la relación riesgo/beneficio debe hacerse caso por caso, sopesando el riesgo del tratamiento con hidroxicarbamida frente al cambio a un programa de transfusiones de sangre.
The evaluation of the risk-benefit ratio should be made on an individual basis outweighing the respective risk of hydroxycarbamide therapy against the switch to a blood transfusion programme.
La exposición total en las 24 horas siguientes a la administración es de 124 mg*h/l en niños y adolescentes y de 135 mg*h/l en pacientes adultos.
The total exposure up to 24 h post-dose is 124 mg*h/l in children and adolescents and 135 mg*h/l in adult patients.
La fecha de caducidad es el último día del mes que se indica.
The expiry date refers to the last day of that month.
La fertilidad en hombres puede verse afectada por el tratamiento.
Fertility in males might be affected by treatment.
La guía de tratamiento para el médico debe contener los siguientes elementos clave:
The treatment guide for physicians should contain the following key elements:
La HbF interfiere en la polimerización de la hemoglobina S (HbS), lo que impide la deformación de los glóbulos rojos.
HbF interferes with the polymerisation of HbS and thus impedes the sickling of red blood cell.
La hemodiálisis redujo la exposición a la hidroxicarbamida en un 33 % (ver secciones 4.2 y 4.4).
Haemodialysis reduced the exposure to hydroxycarbamide by 33% (see sections 4.2 and 4.4)
La hemodiálisis redujo la exposición a la hidroxicarbamida en un 33 % (ver secciones 4.2 y 4.4).
Haemodialysis reduced the exposure to hydroxycarbamide by 33% (see sections 4.2 and 4.4).
La hidroxicarbamida atraviesa la barrera placentaria y se ha demostrado que, en la dosis terapéutica para seres humanos o en otras inferiores, tiene efectos teratógenos y embriotóxicos potentes en gran variedad de modelos con animales.
Hydroxycarbamide crosses the placenta barrier and has been demonstrated to be a potent teratogen and embryotoxic in a wide variety of animal models at or below the human therapeutic dose.
La hidroxicarbamida causa macrocitosis, que puede enmascarar la aparición fortuita de déficit de ácido fólico y vitamina B12.
Hydroxycarbamide causes macrocytosis, which may mask the incidental development of folic acid and vitamin B12 deficiency.
La hidroxicarbamida en concentraciones de 30, 100 y 300 µM no es metabolizada in vitro por el sistema del citocromo P450 de los microsomas hepáticos humanos.
Hydroxycarbamide at 30, 100 and 300 µM is not metabolised in vitro by cytochrome P450s of human liver microsomes.
La hidroxicarbamida es inequívocamente genotóxica en gran variedad de pruebas.
Hydroxycarbamide is unequivocally genotoxic in a wide range of test systems.
La hidroxicarbamida se distribuye rápidamente en el cuerpo humano, entra en el líquido cefalorraquídeo, aparece en el líquido peritoneal y en el ascítico, y se concentra en leucocitos y eritrocitos.
Hydroxycarbamide distributes rapidly throughout the human body, enters the cerebrospinal fluid, appears in peritoneal fluid and ascites, and concentrates in leukocytes and erythrocytes.
La hidroxicarbamida se excreta en la leche materna.
Hydroxycarbamide is excreted in human milk.
La información detallada de este medicamento está disponible en la página web de la Agencia Europea del Medicamento (EMEA): http://www.ema.europa.eu/ También presenta enlaces con otras páginas web sobre enfermedades raras y medicamentos huérfanos.
Detailed information on this medicine is available on the European Medicines Agency website http://www.ema.europa.eu/.
La información detallada de este medicamento está disponible en la página web de la Agencia Europea del Medicamento: http://www.ema.europa.eu.
Detailed information on this medicinal product is available on the website of the European Medicines Agency: http://www.ema.europa.eu.
La mediana de la reducción de los linfocitos CD4 en pacientes tratados con hidroxicarbamida combinada con didanosina, estavudina e indinavir fue de 100/mm3 aproximadamente.
Patients treated with hydroxycarbamide in combination with didanosine, stavudine, and indinavir showed a median decline in CD4 cells of approximately 100/mm3.
La mielosupresión se suele recuperar pronto si se suspende el tratamiento.
Recovery from myelosuppression is usually rapid when therapy is discontinued.
La Mina
Ind. La Mina
La PGR actualizado deberá presentarse con carácter anual
An updated RMP shall be submitted on a yearly basis .
La reacción adversa notificada con más frecuencia es la mielosupresión, siendo la neutropenia su manifestación más frecuente.
The most frequently reported adverse reaction is myelosuppression with neutropenia as the most common manifestation.
La recuperación hematológica suele ocurrir en el plazo de dos semanas.
Haematologic recovery usually occurs within two weeks.
La Selva, 135 17170 Amer (Girona) SPANIEN
Avda la Selva, 135 17170 Amer (Girona) SPAIN
La trombocitopenia y la anemia son menos frecuentes, y es raro que no vayan precedidas por neutropenia.
Thrombocytopenia and anaemia occur less frequently, and are rarely seen without a preceding neutropenia.
La urea es uno de ellos.
Urea is one metabolite of hydroxycarbamide.
La Vallina s/n, Navatejera 24008 León, Spanien
La Vallina s/n, Navatejera 24008 León, Spain
LABEL PÅ FLASKE FILMOVERTRUKNE TABLETTER
BOTTLE LABEL – FILM-COATED TABLETS
LABEL PÅ HÆTTEGLAS MED PROTEIN TIL 12 MG PAKNING
VIAL PROTEIN LABEL FOR 12 MG PACK
LABEL PÅ HÆTTEGLAS MED PROTEIN TIL 4 MG PAKNING
VIAL PROTEIN LABEL FOR 4 MG PACK
Label til 1.000 mg filmovertrukne tabletter i tabletbeholder
Label of 1,000 mg film-coated tablets in tablet containers
Label til 250 mg filmovertrukne tabletter i tabletbeholder
Label of 250 mg film-coated tablets in tablet containers
Label til 500 mg filmovertrukne tabletter i tabletbeholder
Label of 500 mg film-coated tablets in tablet containers
Label til 750 mg filmovertrukne tabletter i tabletbeholder
Label of 750 mg film-coated tablets in tablet containers
LABEL TIL BAKKE (TOPPANEL) TIL 12 MG PAKNING
TRAY TOP LID LABEL FOR 12 MG PACK
LABEL TIL BAKKE (TOPPANEL) TIL 4 MG PAKNING
TRAY TOP LID LABEL FOR 4 MG PACK
LABEL TIL HÆTTEGLAS
VIAL LABEL
LABEL TIL HÆTTEGLAS
VIAL LABEL / Docetaxel Mylan 200 mg/10 ml
Label til pen - ViraferonPeg 100 mikrogram pulver og solvens til injektionsvæske, opløsning i fyldt pen
Pen label - ViraferonPeg 100 micrograms powder and solvent for solution for injection in pre- filled pen
Label til pen - ViraferonPeg 120 mikrogram pulver og solvens til injektionsvæske, opløsning i fyldt pen
Pen label - ViraferonPeg 120 micrograms powder and solvent for solution for injection in pre- filled pen
Label til pen - ViraferonPeg 150 mikrogram pulver og solvens til injektionsvæske, opløsning i fyldt pen
Pen label - ViraferonPeg 150 micrograms powder and solvent for solution for injection in pre- filled pen
Label til pen - ViraferonPeg 50 mikrogram pulver og solvens til injektionsvæske, opløsning i fyldt pen
Pen label - ViraferonPeg 50 micrograms powder and solvent for solution for injection in pre- filled pen
Label til pen - ViraferonPeg 80 mikrogram pulver og solvens til injektionsvæske, opløsning i fyldt pen
Pen label - ViraferonPeg 80 micrograms powder and solvent for solution for injection in pre- filled pen
Label til tabletbeholder
Label for tablet container
Labetalolhydrochlorid
Labetalol HCl
Laboratoire de Toulouse 4, Chemin du Calquet 31300 TOULOUSE FRANKRIG
Laboratoire de Toulouse 4 Chemin du Calquet 31300 TOULOUSE FRANCE‌‌
Laboratoire GlaxoSmithKline Tél: + 33 (0)1 39 17 84 44 diam@gsk.com
Tél.: + 33 (0)1 39 17 84 44 diam@gsk.com
Laboratoire HRA Pharma Tlf.: + 33 1 40 33 11 30 lysodren@hra-pharma.com
Laboratoire HRA Pharma Tel: + 33 1 40 33 11 30 lysodren@hra-pharma.com
Laboratoire Lyon Gerland 254 rue Marcel Mérieux F-69007 LYON
Laboratoire Lyon Gerland 254, rue Marcel Mérieux F-69007 Lyon
Laboratoire Lyon Porte des Alpes Rue de l’Aviation,
Laboratory of Lyon Porte des Alpes Rue de l’Aviation,
Laboratoire Porte des Alpes Rue de l'Aviation
Laboratoire Porte des Alpes
Laboratoire Porte des Alpes Rue de l’Aviation
Laboratoire Porte des Alpes
Laboratoire Porte des Alpes Rue de l’Aviation
Laboratoire Porte des Alpes Rue de l'Aviation
Laboratoire Porte des Alpes, Rue de l'Aviation,
Laboratoire Porte des Alpes Rue de l'Aviation
Laboratoires BIOCODEX 1 avenue Blaise Pascal, 60000 Beauvais FRANKRIG‌
Laboratoires BIOCODEX 1 avenue Blaise Pascal, 60000 Beauvais FRANCE
Laboratoires Porte des Alpes Rue de l’Aviation
Laboratoire Porte des Alpes Rue de l'Aviation
Laboratoires Porte des Alpes Rue de l’Aviation
Laboratoire Porte des Alpes Rue de l’aviation
Laboratoires SMB s.a. rue de la Pastorale, 26-28 B-1080 Bruxelles Belgien
Laboratoires SMB s.a. rue de la Pastorale, 26-28 B-1080 Brussels Belgium
Laboratorie bivirkninger
Laboratory adverse events
Laboratorie- parametre
Laboratory parameter
Laboratorieanalyser: Patientens elektrolyt- og glykæmiske niveauer samt hæmatologiske, hepatiske, renale og koagulationsparameteranalyser skal kontrolleres mindst to gange om ugen og oftere for klinisk ustabile patienter under induktionsfasen og mindst ugentligt under konsolideringsfasen.
Laboratory tests: The patient’s electrolyte and glycaemia levels, as well as haematologic, hepatic, renal and coagulation parameter tests must be monitored at least twice weekly, and more frequently for clinically unstable patients during the induction phase and at least weekly during the consolidation phase.
Laboratorieanomalier hos SJIA-patienter Hæmatologi
Laboratory abnormalities in SJIA patients Haematology
Laboratorieanomalier hos urinsyregigt-patienter Hæmatologi
Laboratory abnormalities in gouty arthritis patients Haematology
Laboratorieanormaliteter, der betragtes som bivirkninger, er anført i et afsnit under tabel 2.
Laboratory abnormalities considered ADRs are included in a paragraph below table 2.
Laboratoriebaserede undersøgelser af sikkerheden påviste ingen interaktion, når sarolaner blev administreret samtidigt med milbemycinoxim, moxidectin og pyrantelpamoat. (I disse undersøgelser effekt ikke blev undersøgt.)
In laboratory safety studies, no interactions were observed when sarolaner was co-administered with milbemycin oxime, moxidectin and pyrantel pamoate. (In these studies efficacy was not investigated).
Laboratoriebestemmelse af neutropeni og trombocytopeni
Laboratory assessment of neutropenia and thrombocytopenia
Laboratorieforsøg med drægtige rotter har vist tegn på dosisafhængig skadelig virkning på drægtige rotter og deres fostre ved høje doser (40 og 160 milligram pr. kg indgivet dagligt i 10 dage).
Laboratory studies in pregnant rats administered high dosages (40 and 160 mg/kg daily for 10 days) have shown evidence of dose-related harmful effects to the pregnant rat and to the embryo/foetus.
Laboratorieforsøg med rotter og kaniner har ikke vist tegn på misdannelser af fosteret.
Laboratory studies in rats and rabbits have not produced any evidence of any teratogenic effects.
Laboratoriefund
Laboratory evaluations
Laboratoriefund Nedsat antal lymfocytter
Laboratory findings Decrease in lymphocyte counts
Laboratoriekontrol
Laboratory monitoring
laboratoriemæssig monitorering
laboratory monitoring for
laboratoriemæssig monitorering
relevance of the
Laboratorienudesøgelse
Investigations
Laboratorieparameter (i % af undersøgte prøver)
Laboratory parameter (in % of samples investigated)
Laboratorieparameter Graduering
Laboratory Parameters Grading
Laboratorieparametre, såsom højt niveau af CRP og SAA, høje neutrofil- og trombocyttal, normaliseredes hurtigt inden for nogle dage efter injektion af Ilaris.
Laboratory parameters such as high CRP and SAA, high neutrophils and platelet counts normalised rapidly within days of Ilaris injection.
Laboratorieparametrene hos disse 4 personer med bevis for proksimal tubulopati forbedredes uden kliniske konsekvenser ved seponering af Stribild, men normaliseredes ikke helt hos alle personer.
4 subjects with evidence of proximal tubulopathy improved without clinical consequence upon discontinuation of Stribild, but did not completely resolve in all subjects.
Laboratorieresultater:
Laboratory results
Laboratories Cyclopharma, 31000, Toulouse, Frankrig
Laboratories Cyclopharma, 31000, Toulouse, France
Laboratories Cyclopharma, 80440, Glisy, Frankrig
Laboratories Cyclopharma, 80440, Glisy, France
Laboratories Cyclopharma– Toulouse 3 Place Pierre Potier
Laboratories Cyclopharma – Toulouse 3 Place Pierre Potier
Laboratoriestudier af rotter og kaniner har ikke afsløret tegn på fostermisdannende, fosterskadende eller moderskadende virkning.
Laboratory studies in rats and rabbits have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects.
Laboratoriestudier har vist at administration af produktet i den tidlige drægtighed hos tæven sandsynligvis ikke har effekt på drægtigheden (drægtigheden vil fortsætte til termin med fødsel af levedygtige hvalpe).
Laboratory studies have shown that administration of the product during early pregnancy in the bitch is unlikely to affect that pregnancy (that is, pregnancy will be carried to full term with the birth of viable pups).
Laboratoriestudier i mus og rotter viste tegn på embryotoksisk effekt .
Laboratory animal studies in mice and rats have shown evidence of embryotoxic effects.
Laboratoriestudier i mus og rotter viste tegn på embryotoksisk effekt.
Laboratory studies in mice and rats have shown evidence of embryotoxic effects.
Laboratoriestudier med rotter og kaniner har ikke vist tegn på påvirkning på forplantningsevnen hos handyr og hundyr.
Laboratory studies in rats and rabbits have not produced any evidence of any effect on the reproductive capacity in males and females.
Laboratorietest
Lab test
Laboratorietest
Laboratory effects
Laboratorietest for leverfunktion, inklusive niveau af konjugeret bilirubin skal udføres ved baseline, i løbet af de første 4 ugers behandling og herefter, når det er klinsik indiceret.
Hepatic laboratory testing including direct bilirubin levels should be performed at baseline, during the first 4 weeks of starting treatment and as clinically indicated thereafter.
Laboratorietest under behandling med OLYSIO, peginterferon alfa og ribavirin
Laboratory testing during treatment with OLYSIO, peginterferon alfa and ribavirin
Laboratorieundersøgelser
Investigations
Laboratorieundersøgelser
Laboratory Test
Laboratorieundersøgelser
Medical tests
Laboratorieundersøgelser (rotter, mus og kaniner) med indoxacarb og permethrin har ikke vist tegn på teratogen, føtotoksisk eller maternotoksisk effekt.
Laboratory animal studies (rats, mice and rabbits) with indoxacarb and permethrin have not produced any evidence of a teratogenic, foetotoxic or materno toxic effects.
Laboratorieundersøgelser af dyr har ikke afsløret holdepunkter for en teratogenicitet.
Laboratory studies in animals have not produced any evidence of a teratogenic effect.
Laboratorieundersøgelser af dyr har ikke påvist teratogene virkninger.
Laboratory studies in animals have not produced any evidence of a teratogenic effect.
Laboratorieundersøgelser af dyr, der har fået andre NSAID’ere, har dog vist øget hyppighed af præ- og postimplantationstab, embryo/føtal letalitet og misdannelser.
However, studies in laboratory animals administered other NSAIDs have shown increased pre- and post-implantation loss, embryo-foetal lethality, and malformations.
Laboratorieundersøgelser af mus har ikke afsløret teratogene virkninger, føtal toksicitet eller maternel toksicitet.
Laboratory studies in mice have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects.
Laboratorieundersøgelser af rotter og kaniner har ikke afsløret fosterskadende virkninger eller bivirkninger på avlssevnen hos hanner og hunner.
Laboratory studies in rats and rabbits have not produced any evidence of birth defects, or any adverse effect on the reproductive capacity in males and females.
Laboratorieundersøgelser af rotter og kaniner har ikke afsløret tegn på fosterskader eller nogen bivirkninger på reproduktionsevnen hos hanner og hunner.
Laboratory studies in rats and rabbits have not produced any evidence of teratogenic effects, or any adverse effect on the reproductive capacity of males and females.
Laboratorieundersøgelser før og under behandlingen
Laboratory tests prior to and during therapy
Laboratorieundersøgelser i hundehvalpe har påvist tegn på arthropati efter systemisk indgivelse af flouroquinoloner.
Laboratory studies in puppies have shown evidence of arthropathy after systemic administration of fluoroquinolones.
Laboratorieundersøgelser kan vise unormale ændringer i cellerne i din knoglemarv.
Laboratory tests may show abnormal changes to the cells in your bone marrow.
Laboratorieundersøgelser kan vise:
Tests may show: